Does NELARABINE Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with NELARABINE (Nelarabine). This represents 0.7% of all adverse event reports for NELARABINE.
5
Reports of Second primary malignancy with NELARABINE
0.7%
of all NELARABINE reports
0
Deaths
3
Hospitalizations
How Dangerous Is Second primary malignancy From NELARABINE?
Of the 5 reports, 3 (60.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NELARABINE. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does NELARABINE Cause?
Febrile neutropenia (67)
Drug ineffective (50)
Myelopathy (47)
Neurotoxicity (47)
Neuropathy peripheral (45)
Muscular weakness (42)
Sepsis (39)
Peripheral sensory neuropathy (38)
Neutropenia (37)
Off label use (37)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which NELARABINE Alternatives Have Lower Second primary malignancy Risk?
NELARABINE vs NELFINAVIR
NELARABINE vs NELVUTAMIG
NELARABINE vs NEMOLIZUMAB
NELARABINE vs NEMOLIZUMAB-ILTO
NELARABINE vs NEOMYCIN